ES2175919T3 - Derivados del camptothecin con actividad antitumoral. - Google Patents

Derivados del camptothecin con actividad antitumoral.

Info

Publication number
ES2175919T3
ES2175919T3 ES99830124T ES99830124T ES2175919T3 ES 2175919 T3 ES2175919 T3 ES 2175919T3 ES 99830124 T ES99830124 T ES 99830124T ES 99830124 T ES99830124 T ES 99830124T ES 2175919 T3 ES2175919 T3 ES 2175919T3
Authority
ES
Spain
Prior art keywords
carbon atoms
group
linear
branched alkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99830124T
Other languages
English (en)
Inventor
Sergio Penco
Lucio Merlini
Paolo Carminati
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Application granted granted Critical
Publication of ES2175919T3 publication Critical patent/ES2175919T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de **fórmula**, en donde R1 es un grupo -C(R5)=N-O(n) R4, en donde R4 es un alquilo lineal o ramificado de 1 a 8 átomos de carbono, ó un grupo alquenilo lineal o ramicado de 1 a 8 átomos de carbono, ó cicloalquilo de 3 a10 átomos de carbono, ó un grupo cicloalquilo de 3 a 10 átomos de carbono alquilo lineal o ramificado de 1 a 8 átomos de carbono, ó arilo de 6 a14 átomos de carbono, ó un grupo arilo de 6 a 14 átomos de carbono alquilo lineal o ramificado de 1 a 8 átomos de carbono, o un grupo heterocíclico ó un heterociclo alquilo lineal o ramificado de 1 a 8 átomos de carbono, conteniendo dicho grupo heterocíclico por lo menos un heteroátomo seleccionado del grupo formado por el átomo de nitrógeno, opcionalmente substituido con un grupo alquilode 1 a 8 átomos de carbono, y/o oxígeno y/o azufre; dicho alquilo, alquenilo, cicloalquilo, cicloalquilalquilo, arilo, aril-alquilo, grupos heterocíclicos o heterociclo-alquilo, estando opcionalmente substituidos con uno o más grupos seleccionados del grupo formado por: halógeno, hidroxilo, alquilo de 1 a 8 átomos de carbono, alcoxilo de 1 a 8 átomos de carbono, fenilo, ciano, nitro, -NR6R7, en donde R6 y R7, iguales o diferentes entre sí, son hidrógeno, alquilo lineal o ramificado de 1 a 8 átomos de carbono; el grupo -COOH ó unéster farmacéuticamente aceptable del mismo; o el grupo CONR8R9, en donde R8 y R9 iguales o diferentes entre sí, son hidrógeno, alquilo lineal o ramificado de 1 a 8 átomos de carbono, fenilo; o R4 es un grupo aroilo de 6 a 10 átomos de carbono, o un grupo arilsulfonilo de 6 a 10 átomos de carbono, opcionalmente substituido con uno o más grupos seleccionados del grupo formado por: halógeno, hidroxilo, alquilo lineal o ramificado de 1 a 8 átomos de carbono, alcoxilo lineal o ramificado de 1 a 8 átomos de carbono, fenilo, ciano, nitro, -NR10R11, en donde R10 y R11, iguales o diferentes entre sí, son hidrógeno, alquilo lineal o ramificado de 1 a 8 átomos de carbono; R4 es un grupo poliaminoalquilo de fórmula -(CH2)m-NR12-(CH2)p-NR13-(CH2)q-NH2, en donde m, p son un número entero de 2 a 6, y q es un número entero de 0 a 6, ambos incluidos, y R12 y R13 son un grupo alquilo lineal o ramificado de 1 a 8 átomos de carbono; o R4 es un grupo glicosilo seleccionado entre 6-D-galactosilo, 6-D-glucosilo; n es el número 1; R5 es hidrógeno,alquilolinealo ramificado de 1 a 8 átomos de carbono, alquenilo lineal o ramificado de 1 a 8 átomos de carbono, cicloalquilo de 3 a 10 átomos de carbono, cicloalquilo de 3 a 10 átomos de carbono-alquilolinealo ramificado de 1 a 8 átomos de carbono, arilo de 6 a 14 átomos de carbono, arilo de 6 a 14 átomos de carbono alquilo lineal o ramificado de 1 a 8 átomos de carbono; R2 y R3, iguales o diferentes entre sí, son hidrógeno, hidroxilo, alcoxilo lineal o ramificado de 1 a 8 átomos de carbono; sus óxidos N1, sus isómeros únicos, en particular los isómeros s y n y anti del grupo -C(R5)=N-O(n) R4, sus posibles enantiómeros, diastereoisómeros y mezclas relativas, y salesfarmacéuticamente aceptables de los mismos.
ES99830124T 1999-03-09 1999-03-09 Derivados del camptothecin con actividad antitumoral. Expired - Lifetime ES2175919T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity

Publications (1)

Publication Number Publication Date
ES2175919T3 true ES2175919T3 (es) 2002-11-16

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99830124T Expired - Lifetime ES2175919T3 (es) 1999-03-09 1999-03-09 Derivados del camptothecin con actividad antitumoral.

Country Status (38)

Country Link
US (2) US6242457B1 (es)
EP (1) EP1044977B1 (es)
JP (1) JP4610743B2 (es)
KR (1) KR100702085B1 (es)
CN (1) CN1139592C (es)
AR (1) AR022860A1 (es)
AT (1) ATE216998T1 (es)
AU (1) AU774174B2 (es)
BG (1) BG65032B1 (es)
BR (1) BR0008840B1 (es)
CA (1) CA2362760C (es)
CO (1) CO5180590A1 (es)
CZ (1) CZ304465B6 (es)
DE (1) DE69901379T2 (es)
DK (1) DK1044977T3 (es)
EA (1) EA003605B1 (es)
EE (1) EE04679B1 (es)
EG (1) EG23999A (es)
ES (1) ES2175919T3 (es)
HR (1) HRP20010667B1 (es)
HU (1) HU229506B1 (es)
IL (2) IL144958A0 (es)
IS (1) IS2003B (es)
ME (2) ME00017B (es)
MX (1) MXPA01009081A (es)
NO (1) NO328363B1 (es)
NZ (1) NZ513393A (es)
PE (1) PE20001485A1 (es)
PL (1) PL222208B1 (es)
PT (1) PT1044977E (es)
RS (1) RS50405B (es)
SI (1) SI1044977T1 (es)
SK (1) SK287561B6 (es)
TN (1) TNSN00045A1 (es)
TR (1) TR200102603T2 (es)
TW (1) TWI272272B (es)
WO (1) WO2000053607A1 (es)
ZA (1) ZA200107408B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
CA2559532A1 (en) * 2004-03-26 2005-10-06 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9－硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
MX2007007212A (es) * 2004-12-15 2007-11-07 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento del cancer.
JP5491699B2 (ja) * 2004-12-21 2014-05-14 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 立体選択的方法およびカンプトテシンの結晶形態
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
NZ562951A (en) 2005-07-14 2011-09-30 Wellstat Biologics Corp Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination
AU2006274509B2 (en) * 2005-07-27 2012-01-19 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
RU2008108894A (ru) * 2005-08-10 2009-09-20 Новартис АГ (CH) Композиции 7-(трет-бутокси)иминометилкамптотецина
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
PL1962850T3 (pl) * 2005-12-21 2012-07-31 Sigma Tau Ind Farmaceuti Leczenie lekoopornych nowotworów
JP5596924B2 (ja) 2006-02-17 2014-09-24 カスケード プロドラッグ インコーポレイテッド ビンカアルカロイドｎ酸化物および類似体による過剰増殖疾患の処置
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
WO2009015981A2 (en) * 2007-08-01 2009-02-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of pediatric tumors
EP2096113A1 (en) 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
CA2995029C (en) 2015-09-25 2022-10-25 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2025252101A1 (zh) * 2024-06-05 2025-12-11 荣昌生物制药(烟台)股份有限公司 一种喜树碱类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
WO1993009782A1 (en) * 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
IL127800A (en) * 1996-08-19 2005-11-20 Bionumerik Pharmaceuticals Inc Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IS6031A (is) 2001-07-31
BG105810A (en) 2002-06-28
US6242457B1 (en) 2001-06-05
ZA200107408B (en) 2002-05-29
CA2362760C (en) 2009-08-18
AR022860A1 (es) 2002-09-04
CN1139592C (zh) 2004-02-25
RS50405B (sr) 2009-12-31
HK1031222A1 (en) 2001-06-08
NZ513393A (en) 2003-04-29
HU229506B1 (en) 2014-01-28
TWI272272B (en) 2007-02-01
JP2002539128A (ja) 2002-11-19
SK11642001A3 (sk) 2002-01-07
TR200102603T2 (tr) 2002-01-21
KR100702085B1 (ko) 2007-04-02
EA003605B1 (ru) 2003-06-26
ATE216998T1 (de) 2002-05-15
IS2003B (is) 2005-04-15
MEP4008A (xx) 2010-02-10
US20010008939A1 (en) 2001-07-19
HUP0200210A3 (en) 2004-03-29
YU64301A (sh) 2005-07-19
NO20014128D0 (no) 2001-08-24
DK1044977T3 (da) 2002-07-08
ME00017B (me) 2010-06-10
PL222208B1 (pl) 2016-07-29
EA200100954A1 (ru) 2002-04-25
PL355094A1 (en) 2004-03-22
KR20010102519A (ko) 2001-11-15
EG23999A (en) 2008-03-19
CN1343209A (zh) 2002-04-03
HRP20010667A2 (en) 2002-08-31
BG65032B1 (bg) 2006-12-29
HRP20010667B1 (en) 2003-06-30
CA2362760A1 (en) 2000-09-14
BR0008840A (pt) 2002-01-08
EP1044977B1 (en) 2002-05-02
CZ20013077A3 (cs) 2002-01-16
IL144958A0 (en) 2002-06-30
HUP0200210A2 (hu) 2002-05-29
CZ304465B6 (cs) 2014-05-21
IL144958A (en) 2009-08-03
EE200100466A (et) 2002-12-16
SI1044977T1 (en) 2002-08-31
AU3160400A (en) 2000-09-28
US6589939B2 (en) 2003-07-08
EP1044977A1 (en) 2000-10-18
DE69901379T2 (de) 2002-11-07
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
DE69901379D1 (de) 2002-06-06
EE04679B1 (et) 2006-08-15
PE20001485A1 (es) 2000-12-07
TNSN00045A1 (fr) 2005-11-10
CO5180590A1 (es) 2002-07-30
MXPA01009081A (es) 2002-08-30
WO2000053607A1 (en) 2000-09-14
BR0008840B1 (pt) 2011-12-27
NO20014128L (no) 2001-08-24
JP4610743B2 (ja) 2011-01-12
SK287561B6 (sk) 2011-02-04
AU774174B2 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
NZ513393A (en) Camptothecin derivatives having antitumor activity
AR012032A1 (es) Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion
FI865037A7 (fi) Mikrobicida kompositioner.
NO953447L (no) Nye 4-aminopyridiner, fremgangsmåte for deres fremstilling samt legemidler inneholdende disse
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
AR055878A1 (es) Derivados de ciclopropanocarboxamida
NZ512731A (en) Tricyclic inhibitors of poly(ADP-ribose) polymerases
FI882081A0 (fi) 2-substituerade e-fusionerade (1,2,4) triazolo(1,5-c) pyrimidiner, farmaceutiska kompositioner och deras anvaendning.
PT1178967E (pt) Derivados de quinolina como inibidores de enzimas mek
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
IE41928L (en) Esters of 1-acylpiperazine-4-carboxylic acids
NZ336837A (en) Photochromic heterocyclic fused indenonaphthopyrans and photochromic articles thereof
NZ228331A (en) Amine- and amido-containing heterocyclic compounds and pharmaceutical compositions
BG102792A (bg) Производни на заместени 4-хидроксифенилалканоилови киселини с агонистична активност към рраr-гама
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO4810298A1 (es) Nuevas amidas aromaticas y su procedimiento de preparacion .
AR002745A1 (es) 5,6-DIHIDRO-9H-PIRAZOL[3,4-c]-1,2,4-TRIAZOL [4,3-a] PIRIDINAS TRICICLICAS Y COMPOSICIONES FARMACEUTICAS CONTENIENDO LAS MISMAS.
EA200101224A1 (ru) Производные пурина, способ их получения и содержащие их фармацевтические композиции
AR040140A1 (es) Derivados de esteres de camptotecina en la posicion 20
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
AR040139A1 (es) Camptotecinas con un anillo lactona modificado
CO5611121A2 (es) Derivados de fenil amidas con silicio utiles como microbicidas
DK0805153T3 (da) Hidtil ukendte muskarine receptoragonister
AR062743A1 (es) Esteres de nitrato de aminoalcoholes
FI853685A0 (fi) Nya n-alk(en)yl-n-(o,o-disubstituerade -tiofosforyl)-n'n'-disubstituerade glycinamider, foerfarande foer framstaellning av dessa samt kvalstergifter, insektgifter och svampgifter vilka innehaoller dessa som aktiv bestaondsdel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1044977

Country of ref document: ES